Biotechnology
Patronus Biotech receives grant to evaluate a novel malaria vaccine and adjuvant to support affordable access and use in global health
SINGAPORE, Nov. 27, 2025 /PRNewswire/ -- Patronus Biotech today announced a grant from the Gates Foundation to accelerate the development of its novel malaria vaccine and adjuvant program to support affordable access and use in global health. The funding will enable the evaluation of an innovativ...
2025-11-27 09:00
784
TCI Biotech Inaugurates Advanced Performance Nutrition Research Center, Expands Into Brain Science to Accelerate Next-Generation Health Innovation
SALT LAKE CITY, Nov. 26, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.), a global CDMO+ specializing in functional foods, nutraceuticals, and beauty supplementation, today announced the launch of the TCI Advanced Performance Nutrition Research Center, a new innovation hub focused on high-perfor...
2025-11-27 00:00
822
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
* Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) * Findings support the therapeutic potential of ZYMFENTRA in addressing ...
2025-11-26 14:48
1425
Korea Innovation Foundation selects 2 Innovative bio health companies, LEEBIO, and Airlab for Global Technology Commercialization Support Program (North America)
DAEJEON, South Korea, Nov. 26, 2025 /PRNewswire/ -- Korea Innovation Foundation (INNOPOLIS), currently operating the 2025 Global Technology Commercialization Support Program (North America), announces that 2 innovative companies, LEEBIO, and Airlab are chosen for the support program. This initia...
2025-11-26 13:45
774
Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America
SINGAPORE, Nov. 26, 2025 /PRNewswire/ -- Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered inBuenos Aires, Argentina, with decades of experience in ...
2025-11-26 09:06
1254
Professor Chan Heum Park's Team at Hallym University Chuncheon Sacred Heart Hospital Sends Their Self-Developed "BioCabinet" to Space Aboard Nuri Rocket
SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- Chan Hum Park, M.D., Ph.D., Professor of Otolaryngology at Hallym University Chuncheon Sacred Heart Hospital and Director of the Nano-Bio Regenerative Medical Institute at Hallym University, leads the research team whose space biology payload, Bio...
2025-11-26 07:30
943
Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911
SHANGHAI, Nov. 25, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its independently developed novel CDH17-targeting antibody-drug ...
2025-11-25 22:00
881
Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
* Pharmaplan fully integrated into Exyte, unifying biopharma engineering capabilities under one European organization. * Integrated setup drives strong client demand and a record order-intake level in 2025. * End-to-end EPC/EPCM delivery from feasibility to qualified handover across key lif...
2025-11-25 18:00
958
Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2025-11-25 17:00
912
HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization
* The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platf...
2025-11-25 00:30
1171
ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
* Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology * Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- ToolGen Inc. (K...
2025-11-24 22:00
1060
Pinnacle Food Announces New Strategic Initiative to Expand its Smart Agriculture Innovation Platform
VANCOUVER, BC, Nov. 24, 2025 /PRNewswire/ -- Pinnacle Food Group Limited (NASDAQ:PFAI) announced a strategic initiative to establish a bioengineering and testing laboratory. The Company is exploring applied bioengineering initiatives to further expand its smart agriculture innovation platform int...
2025-11-24 21:00
807
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tiru...
2025-11-24 20:00
1054
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced onNovember 20 that it has administered the f...
2025-11-24 15:11
787
GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
* Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology * Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea and HONG KONG, Nov. 24, 2025 /PRNewswire/ -- G...
2025-11-24 08:00
1195
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 22, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...
2025-11-22 20:28
1740
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 21, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...
2025-11-22 06:32
2119
BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
* Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years. * Demonstrating Robust Capabilities: Throughout the collaboration, all technology transfers and GMP manufact...
2025-11-21 21:00
1275
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) inYokohama, Japan, the Company's first cyclotron facility in theAsia Pacific region (APAC...
2025-11-21 14:22
3003
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
* Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program * The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity ...
2025-11-21 13:46
978
Week's Top Stories
Most Reposted
Tonik raises US$12M Pre-Series C to scale capital-efficient lending in the Philippines
[Picked up by 318 media titles]
2025-12-04 10:15
Hyundai Motor Group and Air Liquide Advance Global Partnership to Accelerate Hydrogen Ecosystem
[Picked up by 310 media titles]
2025-12-04 16:00
Klook takes the lead among international travelers booking paid tours and activities in Japan
[Picked up by 309 media titles]
2025-12-04 13:12
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 297 media titles]
2025-12-03 09:00
Hyundai Motor Group Fosters Collaboration with Hydrogen Industry Leaders at Hydrogen Council Global CEO Summit
[Picked up by 295 media titles]
2025-12-04 15:00
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
3968
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3301
